hunTR® Platform
Alaunos’ hunTR® (human neoantigen T-cell Receptor) platform enables the rapid identification of new, wholly owned TCRs to further expand the Company’s growing TCR library. hunTR® is able to interrogate and deconvolute thousands of single T cells simultaneously using state-of-the-art bioinformatics and next generation sequencing. The TCRs from both CD4+ and CD8+ T cells are to maximize breadth of the TCR library. There is no need to expand TILs in this approach, so populations that do not expand ex vivo can be evaluated. This proprietary high-throughput TCR screening process permits rapid functional validation of TCRs. Based on this process Alaunos will be able to rapidly advance new TCR library candidates from the lab through to clinical translation.
We are dedicated to developing the next generation of TCR-T cell therapies through a robust R&D engine
Our hunTR® (human neoantigen T-cell Receptor) platform harnesses our state-of-the-art TCR discovery process with a proprietary high-throughput TCR functional validation to streamline the addition of exclusively owned, high-quality TCRs to our existing TCR-T cell therapy infrastructure. We are augmenting TCR-T cells through co-expression of membrane-bound interleukin-15 (mbIL-15) on the TCR-T cell surface. Immune monitoring and in-depth clinical biomarker analyses of tumors from patients treated on our TCR-T cell therapy clinical trial aim to inform on additional next-generation efforts. We are dedicated to improving and maximizing the power of TCR-T cell therapy for cancer patients.